The effect of Zhangfei/CREBZF on cell growth, differentiation, apoptosis, migration, and the unfolded protein response in several canine osteosarcoma cell lines

Por Zhang, Rui, Thamm, Douglas H, Misra, Vikram
Publicado no BMC Vet Res (2015)

Autophagy and Cancer Therapy

Por Thorburn, Andrew, Thamm, Douglas H., Gustafson, Daniel L.
Publicado em 2014

Systems biology approach to identification of biomarkers for metastatic progression in cancer

Por Ptitsyn, Andrey A, Weil, Michael M, Thamm, Douglas H
Publicado em 2008

Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer

Por Wittenburg, Luke A., Gustafson, Daniel L., Thamm, Douglas H.
Publicado em 2010

The immunosignature of canine lymphoma: characterization and diagnostic application

Por Johnston, Stephen Albert, Thamm, Douglas H, Legutki, Joseph Barten
Publicado em 2014

A Systems Biology Approach to Identify Molecular Pathways Altered by HDAC Inhibition in Osteosarcoma

Por Wittenburg, Luke A., Ptitsyn, Andrey A., Thamm, Douglas H.
Publicado no J Cell Biochem (2012)

Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone

Por Webster, Joshua D, Yuzbasiyan-Gurkan, Vilma, Thamm, Douglas H, Hamilton, Elizabeth, Kiupel, Matti
Publicado em 2008

The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin

Por Wittenburg, Luke A., Bisson, Liam, Rose, Barbara J., Korch, Christopher, Thamm, Douglas H.
Publicado em 2010

An Asymmetric Synthesis of 1,2,4-Trioxane Anticancer Agents via Desymmetrization of Peroxyquinols through a Brønsted Acid Catalysis Cascade

Por Rubush, David M., Morges, Michelle A., Rose, Barbara J., Thamm, Douglas H., Rovis, Tomislav
Publicado em 2012

DNA Repair Deficiency as a Susceptibility Marker for Spontaneous Lymphoma in Golden Retriever Dogs: A Case-Control Study

Por Thamm, Douglas H., Grunerud, Kristen K., Rose, Barbara J., Vail, David M., Bailey, Susan M.
Publicado em 2013

Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma

Por Barnard, Rebecca A, Wittenburg, Luke A, Amaravadi, Ravi K, Gustafson, Daniel L, Thorburn, Andrew, Thamm, Douglas H
Publicado em 2014

Intrinsic Radiosensitivity and Cellular Characterization of 27 Canine Cancer Cell Lines

Por Maeda, Junko, Froning, Coral E., Brents, Colleen A., Rose, Barbara J., Thamm, Douglas H., Kato, Takamitsu A.
Publicado no PLoS One (2016)

GS-9219/VDC-1101 - a prodrug of the acyclic nucleotide PMEG has antitumor activity inspontaneous canine multiple myeloma

Por Thamm, Douglas H, Vail, David M, Kurzman, Ilene D, Babusis, Darius, Ray, Adrian S, Sousa-Powers, Noel, Tumas, Daniel B
Publicado em 2014

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor

Por Halsey, Charles HC, Gustafson, Daniel L, Rose, Barbara J, Wolf-Ringwall, Amber, Burnett, Robert C, Duval, Dawn L, Avery, Anne C, Thamm, Douglas H
Publicado em 2014

Relative biological effectiveness in canine osteosarcoma cells irradiated with accelerated charged particles

Por Maeda, Junko, Cartwright, Ian M., Haskins, Jeremy S., Fujii, Yoshihiro, Fujisawa, Hiroshi, Hirakawa, Hirokazu, Uesaka, Mitsuru, Kitamura, Hisashi, Fujimori, Akira, Thamm, Douglas H., Kato, Takamitsu A.
Publicado no Oncol Lett (2016)

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Por Honigberg, Lee A., Smith, Ashley M., Sirisawad, Mint, Verner, Erik, Loury, David, Chang, Betty, Li, Shyr, Pan, Zhengying, Thamm, Douglas H., Miller, Richard A., Buggy, Joseph J.
Publicado em 2010

HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors

Por Dailey, Deanna D, Anfinsen, Kristin P, Pfaff, Liza E, Ehrhart, EJ, Charles, J Brad, Bønsdorff, Tina B, Thamm, Douglas H, Powers, Barbara E, Jonasdottir, Thora J, Duval, Dawn L
Publicado em 2013

Comparative Pharmacokinetic Properties and Antitumor Activity of the Marine HDACi Largazole and Largazole Peptide Isostere

Por Pilon, John L., Clausen, Dane J., Hansen, Ryan J., Lunghofer, Paul J., Charles, Brad, Rose, Barbara J., Thamm, Douglas H., Gustafson, Daniel L., Bradner, James E., Williams, Robert M.
Publicado no Cancer Chemother Pharmacol (2015)

Genomic Instability and Telomere Fusion of Canine Osteosarcoma Cells

Por Maeda, Junko, Yurkon, Charles R., Fujisawa, Hiroshi, Kaneko, Masami, Genet, Stefan C., Roybal, Erica J., Rota, Garrett W., Saffer, Ethan R., Rose, Barbara J., Hanneman, William H., Thamm, Douglas H., Kato, Takamitsu A.
Publicado em 2012

Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma

Por Gardner, Heather L., London, Cheryl A., Portela, Roberta A., Nguyen, Sandra, Rosenberg, Mona P., Klein, Mary K., Clifford, Craig, Thamm, Douglas H., Vail, David M., Bergman, Phil, Crawford-Jakubiak, Martin, Henry, Carolyn, Locke, Jennifer, Garrett, Laura D.
Publicado no BMC Vet Res (2015)